Working… Menu

FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (FLAT-SUGAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01524705
Recruitment Status : Completed
First Posted : February 2, 2012
Last Update Posted : September 18, 2014
Eli Lilly and Company
Astra Zeneca, Bristol-Myers Squibb
DexCom, Inc.
Becton, Dickinson and Company
University of Texas
US Department of Veterans Affairs
Biomedical Research Institute of New Mexico
Information provided by (Responsible Party):
Jeff Probstfield, University of Washington

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : July 2014
Actual Study Completion Date : July 2014
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 April 21, 2017
(Canceled - Date Unknown)
April 24, 2017
May 31, 2017
2 October 12, 2017
November 13, 2017
3 April 30, 2018
June 1, 2018
4 August 17, 2020
August 26, 2020

Publications automatically indexed to this study by Identifier (NCT Number):